冠心Ⅰ号治疗心脉痹阻型冠心病的临床疗效及安全性  

Clinical efficacy and safety of Guanxin No.1 on coronary heart disease of the Xinmai Bizu type

作　　者：吴亚芬 Wu Yafen

机构地区：[1]中国政法大学校医院

出　　处：《中医临床研究》2019年第26期42-44,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:研究冠心Ⅰ号治疗心脉痹阻型冠状动脉粥样硬化性心脏病(简称冠心病)的临床疗效及安全性。方法:选择100例心脉痹阻型冠心病患者作为本次研究对象,并采用"电脑随机法"将患者进行分组,其中观察组实施冠心Ⅰ号治疗;对照组实施常规治疗。分析两组心绞痛发作频率、硝酸甘油日耗量和ST段压低总和、治疗效果、不良反应以及血液流变学变化。结果:观察组心脉痹阻型冠心病患者心绞痛发作频率、硝酸甘油日耗量、ST段压低总和均优于对照组,P<0.05,两者差异具有统计学意义。观察组心脉痹阻型冠心病患者治疗总有效率较对照组指标更有优势,P<0.05。观察组心脉痹阻型冠心病患者不良反应发生率4.00%,低于对照组不良反应发生率22.00%,差异有统计学意义,P<0.05。观察组心脉痹阻型冠心病患者血液流变学指标优于对照组,P<0.05。结论:冠心Ⅰ号心脉痹阻型冠心病的临床疗效十分显著,且安全性较高,值得研究。Objective:To study Clinical efficacy and safety of Guanxin No.1(冠心Ⅰ号)on coronary heart disease of the Xinmai Bizu type(心脉痹阻型).Methods:100 cases were divided into 2 groups.The control group was given conventional treatment;and the observation group was gievn Guanxin No.1.Results:The frequency of angina pectoris,the daily consumption of nitroglycerin and the total ST segment depression in the observation group were better than those in the control group,P<0.05.The total efficiency in the observation group was higher than that in the control group,P<0.05.The incidence of adverse reactions in the observation group was 4.00%,which was lower than 22.00%in the control group,P<0.05.The blood rheology indexes in the observation group were better,P<0.05.Conclusion:Guanxin No.1 on coronary heart disease of the Xinmai Bizu type shows good effects.

关 键 词：冠心Ⅰ号 心脉痹阻型冠心病 临床疗效 安全性 

分 类 号：R256.22[医药卫生—中医内科学]